<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">finance</journal-id><journal-title-group><journal-title xml:lang="ru">Финансы: теория и практика/Finance: Theory and Practice</journal-title><trans-title-group xml:lang="en"><trans-title>Finance: Theory and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-5671</issn><issn pub-type="epub">2587-7089</issn><publisher><publisher-name>Financial University under The Government of Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26794/2587-5671-2019-23-1-133-146</article-id><article-id custom-type="elpub" pub-id-type="custom">finance-824</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНВЕСТИЦИИ В ИННОВАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INNOVATION  INVESTMENT</subject></subj-group></article-categories><title-group><article-title>Модели оценки рисков деятельности компаний, реализующих проекты с НИОКР</article-title><trans-title-group xml:lang="en"><trans-title>Risk Assessment Models of the Companies Implementing R&amp;D Projects</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6393-145X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минасян</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Minasyan</surname><given-names>V. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виген Бабкенович Минасян — кандидат физико-математических наук, доцент, заведующий кафедрой корпоративных финансов, инвестиционного проектирования и оценки им. М.А. Лимитовского</p><p>Москва</p></bio><bio xml:lang="en"><p>Vigen B. Minasyan — Cand. Sci. (Phis.-Math.), Associate professor, Head of the Corporate Finance, Investment Decisions and Valuation Chair named after M. Limitovsky</p><p>Moscow</p></bio><email xlink:type="simple">minasyanvb@ranepa.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Высшая школа финансов и менеджмента РАНХиГС при Президенте РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Higher School of Finance and Management Russian Academy of National Economy and Public Administration</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>02</month><year>2019</year></pub-date><volume>23</volume><issue>1</issue><fpage>133</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Минасян В.Б., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Минасян В.Б.</copyright-holder><copyright-holder xml:lang="en">Minasyan V.В.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://financetp.fa.ru/jour/article/view/824">https://financetp.fa.ru/jour/article/view/824</self-uri><abstract><p>Компании, реализующие проекты с НИОКР (R&amp;D), сталкиваются с их уникальными особенностями. Среди них: необходимость больших капитальных вложений, длительный срок реализации, высокий потенциал роста, низкая вероятность успеха, трудности с финансированием. Реализация подобных проектов связана с большими рисками. Это приводит к их недофинансированию, так как неопределенность результатов отпугивает инвесторов. Проблема оценки рисков, возникающих при реализации таких проектов, на уровне математических моделей анализа пока недостаточно исследована. Цель статьи — разработка модели, позволяющей исследовать риски, возникающие при реализации компаниями проектов с НИОКР (R&amp;D). Автором разработана модель для оценки подобных рисков при помощи модифицированной для данного применения меры VaR. Получены формулы для расчета данной меры. Они доведены до простых аналитических выражений в предположениях равномерного распределения денежного потока от проекта, или треугольного распределения. Построенная модель учитывает важнейшие причины возникновения рисков в проектах с R&amp;D. Ее можно использовать на практике при предварительной оценке риска проекта еще до его реализации и принятия решения о реализации с учетом риска. Кроме того, данную методику можно использовать и для стандартизации процесса принятия решения о реализации проектов с R&amp;D c учетом «аппетита к риску» с применением меры риска VaR.</p></abstract><trans-abstract xml:lang="en"><p>Companies implementing R&amp;D projects face their unique features. There is the need for large capital investments, long-term implementation, high growth potential, low probability of success, and diffculties in fnancing among them. Implementation of such projects is associated with high risks. This leads to underfunding as uncertain results deter investors. The problem of assessing the risks arising from the implementation of such projects has not yet been suffciently studied at the level of mathematical analysis models. The objective of the article is to develop a model allowing to explore the risks arising from implementing R&amp;D projects. The author has developed a risk assessment model using the VaR measure modifed for this application. The formulas have been obtained to calculate this measure. They have been adjusted to simple analytical expressions assuming the balanced distribution of cash ﬂow from the project, or triangular distribution. The model considers the most important causes of risks in R&amp;D projects. It can be used in a real-case scenario if a preliminary risk assessment of a project is done before its implementation and a decision is made on risk-based implementation. Moreover, this methodology can be used to standardize the decision-making process for the R&amp;D projects implementation considering the “risk appetite” using the VaR risk measure.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>R&amp;D проекты</kwd><kwd>мера риска VaR</kwd><kwd>денежный поток</kwd><kwd>равномерное распределение</kwd><kwd>треугольное распределение</kwd><kwd>носитель распределения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>R&amp;D projects</kwd><kwd>VaR risk measure</kwd><kwd>cash ﬂow</kwd><kwd>balanced distribution</kwd><kwd>triangular distribution</kwd><kwd>distribution carrier</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hall B. H., Lerner J. The financing of R&amp;D and innovation. NBER Working Paper. 2009;(15325). URL: https://www.nber.org/papers/w15325.pdf (дата обращения: 05.12.2018).</mixed-citation><mixed-citation xml:lang="en">Hall B. H., Lerner J. The financing of R&amp;D and innovation. NBER Working Paper. 2009;(15325). URL: https://www.nber.org/papers/w15325.pdf (accessed 05.12.2018).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Thakor R.T., Lo A.W. Optimal fnancing for R&amp;D-intensive frms. NBER Working Paper. 2017;(23831). URL: https://www.nber.org/papers/w23831.pdf (дата обращения: 05.12.2018).</mixed-citation><mixed-citation xml:lang="en">Thakor R.T., Lo A.W. Optimal fnancing for R&amp;D-intensive frms. NBER Working Paper. 2017;(23831). URL: https://www.nber.org/papers/w23831.pdf (accessed оn 05.12.2018).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the pharmaceutical industry: New estimates of R&amp;D costs. Journal of Health Economics. 2016;47(C):20–33. DOI: 10.1016/j.jhealeco.2016.01.012</mixed-citation><mixed-citation xml:lang="en">DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the pharmaceutical industry: New estimates of R&amp;D costs. Journal of Health Economics. 2016;47(C):20–33. DOI: 10.1016/j.jhealeco.2016.01.012</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics. 1991;10(2):107–142. DOI: 10.1016/0167–6296(91)90001–4</mixed-citation><mixed-citation xml:lang="en">DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics. 1991;10(2):107–142. DOI: 10.1016/0167–6296(91)90001–4</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kerr W. R., Nanda R. Financing innovation. Annual Review of Financial Economics. 2015;7:445–462. DOI: 10.1146/annurev-fnancial-111914–041825</mixed-citation><mixed-citation xml:lang="en">Kerr W. R., Nanda R. Financing innovation. Annual Review of Financial Economics. 2015;7:445–462. DOI: 10.1146/annurev-fnancial-111914–041825</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">DiMasi J.A., Reichert J.M., Feldman L., Malins A. Clinical success rates for investigational cancer drugs. Clinical Pharmacology &amp; Therapeutics. 2013;94(3):329–335. DOI: 10.1038/clpt.2013.117</mixed-citation><mixed-citation xml:lang="en">DiMasi J.A., Reichert J.M., Feldman L., Malins A. Clinical success rates for investigational cancer drugs. Clinical Pharmacology &amp; Therapeutics. 2013;94(3):329–335. DOI: 10.1038/clpt.2013.117</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Grabowski H., Vernon J., DiMasi J.A. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(Suppl.3):11–29. DOI: 10.2165/00019053–200220003–00002</mixed-citation><mixed-citation xml:lang="en">Grabowski H., Vernon J., DiMasi J.A. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(Suppl.3):11–29. DOI: 10.2165/00019053–200220003–00002</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Keizer J.A., Halman J.I.M., Song M. From experience: Applying the risk diagnosing methodology. Journal of Product Innovation Management. 2002;19(3):213–232. DOI: 10.1016/S0737–6782(02)00138–8</mixed-citation><mixed-citation xml:lang="en">Keizer J.A., Halman J.I.M., Song M. From experience: Applying the risk diagnosing methodology. Journal of Product Innovation Management. 2002;19(3):213–232. DOI: 10.1016/S0737–6782(02)00138–8</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mastroianni S. A. Risk management among Research and Development projects. Lehigh University. Theses and Dissertations. Paper. 2011;(1299). URL: https://preserve.lehigh.edu/cgi/viewcontent.cgi?article=2299&amp;context=etd (дата обращения: 05.12.2018).</mixed-citation><mixed-citation xml:lang="en">Mastroianni S. A. Risk management among Research and Development projects. Lehigh University. Theses and Dissertations. Paper. 2011;(1299). URL: https://preserve.lehigh.edu/cgi/viewcontent.cgi?article=2299&amp;context=etd (accessed on 05.12.2018).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Choi H., Ahn J. Risk analysis models and risk degree determination in new product development: A case study. Journal of Engineering and Technology Management. 2010;27(1–2):110–124. DOI: 10.1016/j.jengtecman.2010.03.006</mixed-citation><mixed-citation xml:lang="en">Choi H., Ahn J. Risk analysis models and risk degree determination in new product development: A case study. Journal of Engineering and Technology Management. 2010;27(1–2):110–124. DOI: 10.1016/j.jengtecman.2010.03.006</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">McNamee P., Celona J. Decision analysis for the professional. San Jose, CA: SmartOrg, Inc.; 2008. 339 p.</mixed-citation><mixed-citation xml:lang="en">McNamee P., Celona J. Decision analysis for the professional. San Jose, CA: SmartOrg, Inc.; 2008. 339 p.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J., Lin W., Huang Y.-H. A performance- oriented risk management framework for innovative R&amp;D projects. Technovation. 2010;30(11–12):601–611. DOI: 10.1016/j.technovation.2010.07.003</mixed-citation><mixed-citation xml:lang="en">Wang J., Lin W., Huang Y.-H. A performance- oriented risk management framework for innovative R&amp;D projects. Technovation. 2010;30(11–12):601–611. DOI: 10.1016/j.technovation.2010.07.003</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jorion P.Value at risk: The new benchmark for managing fnancial risk. New York: McGraw-Hill Education; 2007. 624 p.</mixed-citation><mixed-citation xml:lang="en">Jorion P. Value at risk: The new benchmark for managing fnancial risk. New York: McGraw-Hill Education; 2007. 624 p.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Круи М., Галай Д., Марк Р. Основы риск-менеджмента. Пер. с англ. М.: Юрайт; 2017. 390 с.</mixed-citation><mixed-citation xml:lang="en">Crouhy M., Galai D., Mark R. The essentials of risk maqnagement. Transl. from Eng. Moscow: Urait; 2017. 390 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hull J.C. Risk management and fnancial institutions. New York: Pearson Education Int.; 2007. 576 p.</mixed-citation><mixed-citation xml:lang="en">Hull J.C. Risk management and fnancial institutions. New York: Pearson Education Int.; 2007. 576 p.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Лимитовский М.А., Минасян В.Б. Анализ рисков инвестиционного проекта. Управление финансовыми рисками. 2011;(2):132–150.</mixed-citation><mixed-citation xml:lang="en">Limitovskii M. A., Minasyan V. B. Investment project risks analysis. Upravlenie finansovymi riskami. 2011;(2):132–150. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Минасян В.Б. Стимулы и моральные риски во взаимоотношениях между принципалом и агентом. Управление финансовыми рисками. 2015;(3):172–184.</mixed-citation><mixed-citation xml:lang="en">Minasyan V. B. Incentives and moral risks in the relationship of a principal and an agent. Upravlenie fnansovymi riskami. 2015;(3):172–184. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
